Tumor cells expressing stress-induced ligands and antibody-opsonized antigens

Tumor cells expressing stress-induced ligands and antibody-opsonized antigens represent a specific physiological state of malignant cells that makes them susceptible to multi-specific immune engagers, particularly those targeting Natural Killer (NK) cells. Stress-induced ligands, such as MHC class I polypeptide-related sequence A (MICA), MICB, and UL16-binding proteins (ULBPs), are upregulated on the surface of cells undergoing oncogenic transformation or DNA damage (PMID: 21439012). Antibody opsonization occurs when therapeutic antibodies bind to tumor-associated antigens, marking the cell for destruction via the Fc receptor CD16 (PMID: 25611325). This dual-target profile is exploited by Tri-specific NK cell Engagers (TriNKETs), which simultaneously bind NKG2D (the receptor for stress ligands) and CD16 on NK cells, while also binding a specific tumor antigen. This mechanism enhances the innate immune system's ability to recognize and eliminate cancer cells that might otherwise evade detection by downregulating single pathways. This target concept is central to the development of therapies designed to create a stable immunological synapse between NK cells and tumor cells, leading to potent and selective cytotoxicity.

Other names

NKG2D ligand-expressing tumor cellsAntibody-opsonized malignant cellsTriNKET-targeted tumor cellsStress-ligand positive cancer cellsNKG2DL-positive tumor cells

Tri-specific engagement of Natural Killer (NK) cells via NKG2D and CD16 receptors to induce targeted lysis of tumor cells expressing stress ligands and specific antigens.